Navigation Links
aTyr Pharma Receives Industry Innovation Awards from TiE and San Diego Venture Group
Date:6/18/2012

SAN DIEGO, June 18, 2012 /PRNewswire/ -- aTyr Pharma, an innovative protein therapeutics business, announced today that aTyr has received two industry awards from TiE and San Diego Venture Group (SDVG) for innovation in life sciences.  The awards recognize the advancements aTyr has made in discovering and developing first-in-class opportunities based on Physiocrine biology. Physiocrines represent new protein therapeutic horizons for auto-immune patients.  

The two awards from TiE and SDVG were competitive on a global and a local level, respectively, and sought to identify and recognize the companies that best represented innovation in a range of industries. TiE, a not-for-profit global network of entrepreneurs and professionals, screened more than 2,100 companies from 37 countries to select 50 of the best companies in five areas: mobile, clean tech, software, social networking and life sciences. aTyr won the award in life sciences for the company's innovation, ingenuity, strong management team and quality of ideas. aTyr was also recently recognized as a "Cool Company" by SDVG which selected, from 150 nominees, 30 companies that represented innovation across all industry sectors in San Diego. 

To learn more about aTyr Pharma, Dr. John Mendlein, aTyr's executive chairman and CEO, will be speaking on a panel called, "Beyond Antibodies: Developing Next Generation Biologics" at the upcoming BIO International Convention in Boston, MA.  The panel will take place June 21 from 8:30 am to 9:45 am EDT in Room 253B. 

About Physiocrines
Physiocrines are produced from ancient genes, aminoacyl tRNA synthetases, an intercellular gene family involved in protein synthesis. Overlooked by genomic discovery efforts, Physiocrines are naturally occurring proteins that modulate extracellular signaling pathways in a variety of physiological processes. These endogenous human proteins act through a variety of receptor classes via mechanisms distinct from current pharmaceuticals and have potential applications in a number of therapeutic areas. aTyr is focused on using Physiocrines to generate effective physiologic responses in immune system disorders, including inflammation and disordered immunity.

About aTyr Pharma
aTyr Pharma develops biologic therapeutics based on Physiocrine biology. aTyr has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr's key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures. For more information, please visit http://www.atyrpharma.com.


'/>"/>
SOURCE aTyr Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Big Pharma and Universities Increasingly Work to Advance Life Science Knowledge by Forming Strategic Partnerships, Public-Private Partnerships, and Open Innovation Programs: Pharmaceutical Research Collaborations Summit
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
4. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
5. Genesis Biopharma Mentioned Favorably in BioMedReports Article
6. Genesis Biopharma Issues Letter To Shareholders
7. New Competitive Arena Emerges for Pharmaceutical Companies in Healthcares Changing Payment Landscape, Finds PwC Health Research Institute Study
8. Questcor Pharmaceuticals Expands Repurchase Program
9. PharmAthene Reports First Quarter 2012 Financial Results
10. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
11. PDL BioPharma to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
Breaking Biology Technology:
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
Breaking Biology News(10 mins):